Draft manuscript - Cambridge University Press



Supplementary Table A 

ADVISORY COMMITTEE

The advisory committee is comprised of senior health and cancer system leaders, experts in biostatistics, health economics, epidemiology, public and private sector finance, and clinical care.

|Member |Title |Organization |

|Jean-Marie Berthelot |Vice-President, Programs |Canadian Institute for Health Information |

|Jacques Brisson |Researcher, Centre de Recherche, Hôpital du Saint-Sacrement |Laval University |

|Adalsteinn Brown |Assistant Deputy Minister, Health System Strategy Division |Ontario Ministry of Health & Long Term Care |

|Andy Coldman |Vice President, Population Oncology |British Columbia Cancer Agency |

|Anthony Fields |Vice President, Cancer Corridor |Alberta Health Services |

|Eva Grunfeld |Director, Knowledge Translation Researcher, Health Services |Cancer Care Ontario and the Ontario |

| |Research Program |Institute for Cancer Research |

|Jon Kerner  |Chair, Primary Prevention Advisory Group; Scientific Advisor|Canadian Partnership Against Cancer |

| |to Cancer Control & Knowledge Management | |

|Anthony Miller |Professor Emeritus |University  of Toronto |

| |Dalla Lana School of Public Health | |

|Steven Ottaway |Head, Healthcare Investment Banking |GMP Securities |

|Stuart Peacock |Director, Health Economics & Cancer Research Program |University of British Columbia |

|Arlene Wilgosh |Former Deputy Minister of Health and Healthy Living |Manitoba Health |

|Timo Hakulinen |Director |Finnish Cancer Registry |

|John McLaughlin |Vice-President, Population Studies and Surveillance |Cancer Care Ontario |

 

Supplementary Table B

TECHNICAL COMMITTEE

The Technical Committee is responsible for assessing the validity and accuracy of the modeling work to ensure transparency of the methods.

|Member |Title |Organization |

|Andy Coldman (Chair) |Vice-President, Population Oncology |British Columbia Cancer Agency|

|Jacques Brisson |Researcher, Centre de Recherche, Hôpital du Saint-Sacrement |Laval University |

|Bernard Candas |Senior Scientific Lead, Cancer Surveillance and Analytic Networks|Canadian Partnership Against |

| | |Cancer |

|Sonya Cressman/Stuart Peacock |Researcher, Centre for Health Economics in Cancer |British Columbia Cancer Agency|

| |Control/Director, Health Economics & Cancer Research Program |University of British Columbia|

|Timo Hakulinen |Director |Finnish Cancer Registry |

|Juanita Hatcher |Director, Surveillance |Alberta Health Services |

|Eric Holowaty |Director, Cancer Surveillance Unit |Cancer Care Ontario |

|Gina Lockwood |Senior Biostatistician and Manager, Analytic Unit |Canadian Partnership Against |

| | |Cancer |

|Anthony Miller |Professor Emeritus |University of Toronto |

| |Dalla Lana School of Public Health | |

|Graham Woodward |Director, Provincial Planning |Cancer Care Ontario |

Supplementary Table C

Table of Key Costs Used in the CRMM Development

(Costs shown in 2008 CAD)

|LUNG CANCER |

|Treatment type |Cost per treatment |

|Surgery lobectomy (Stages I & II) |15245 |

|Surgery Pneumonectomy (Stages I & II) |21324 |

|Radical radiotherapy |4629 |

|Prophylactic cranial irradiation (PCI) |2169 |

|Palliative radiotherapy |1446 |

|Adjuvant chemotherapy |3196 |

|1st line chemotherapy for metastatic cancer |5936 |

|Surveillance (1st year, Stages I & II) |444 |

|End of life care (3 months before death) |2053 |

|End of life care (2 months before death) |4105 |

|End of life care (1 months before death) |7526 |

| |

|SourceL t typecerrpy cancer)r)ore |

|death)ancer44444444444444444444444444444444444444444444444444444444444444444444444444444444444Source: CRMM Lung cancer |

|management workbook version 1.4.0.7 |

| |

| |

| |

| |

| |

| |

| |

| |

| |

| |

| |

|COLON CANCER |

|Treatment type |Cost per treatment |

|Surgical resection (Stages I, II & III) |22786 |

|Adjuvant chemotherapy (Stage III) |15777 |

|1st line chemotherapy for metastatic cancer |31521 |

|Surveillance (1st year, Stage I) |1127 |

|End of life care (3 months before death) |2053 |

|End of life care (2 months before death) |4105 |

|End of life care (1 months before death) |7526 |

| |

|SourceL t typecerrpy cancer)r)ore |

|death)ancer44444444444444444444444444444444444444444444444444444444444444444444444444444444444Source: CRMM Colon cancer |

|management workbook version 1.4.0.7 SourceL t typecerrpy cancer)r)ore |

|death)ancer44444444444444444444444444444444444444444444444444444444444444444444444444444444 |

| |

| |

Note: costs shown above include diagnostics, hospital, physician, drug, radiotherapy, other institutional care, other professional (e.g. nursing, pharmacy) and other (e.g., supplies) costs, wherever applicable.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download